References
- Barbarot S, Auziere S, Gadkari A, et al. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy. 2018;73(6):1284–1293.
- van der Schaft J, Politiek K, van den Reek JMPA, et al. Drug survival for ciclosporin a in a long-term daily practice cohort of adult patients with atopic dermatitis. Br J Dermatol. 2015;172(6):1621–1627.
- Regeneron pharmaceuticals. DUPIXENTVR prescribing information. Tarrytown, NY; 2018 October. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761055s007lbl.pdf
- Patruno C, Fabbrocini G, Longo G, et al. Effectiveness and safety of long-term dupilumab treatment in elderly patients with atopic dermatitis: a multicenter real-life observational study. Am J Clin Dermatol. 2021;22(4):581–586.
- van den Reek JMPA, Kievit W, Gniadecki R, et al. Drug survival studies in dermatology: principles, purposes, and pitfalls. J Invest Dermatol. 2015;135(7):1–5.
- Pereyra-Rodriguez JJ, Domínguez-Cruz J, Ruiz-Villaverde R, et al. Drug survival of systemic and biological treatments for moderate-to-severe atopic dermatitis in adults: a multicentre retrospective observational study. Br J Dermatol. 2021;184(1):175–176.
- Dal Bello G, Maurelli M, Schena D, et al. Drug survival of dupilumab compared to cyclosporin in moderate-to-severe atopic dermatitis patients. Dermatol Ther. 2020;33(6):e13979.
- Spekhorst LS, Ariëns LFM, van der Schaft J, et al. Two-year drug survival of dupilumab in a large cohort of difficult-to-treat adult atopic dermatitis patients compared to cyclosporine a and methotrexate: results from the BioDay registry. Allergy. 2020;75(9):2376–2379.
- Silverberg JI, Guttman-Yassky E, Gadkari A, et al. Real-world persistence with dupilumab among adults with atopic dermatitis. Ann Allergy Asthma Immunol. 2021;126(1):40–45.
- Georgakopoulos JR, Felfeli T, Drucker AM, et al. Two-year efficacy, safety, and drug survival of dupilumab for atopic dermatitis: a real-world Canadian multicenter retrospective study. JAAD Int. 2021;4:67–69.
- Khosravi H, Zhang S, Anderson AM, et al. Dupilumab drug survival, treatment failures, and insurance approval at a tertiary care center in the United States. J Am Acad Dermatol. 2020;82(4):1023–1024.
- Worm M, Simpson EL, Thaçi D, et al. Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(2):131–143.
- Jo CE, Georgakopoulos JR, Ladda M, et al. Evaluation of long-term efficacy, safety, and reasons for discontinuation of dupilumab for moderate to severe atopic dermatitis in clinical practice: a retrospective cohort study. J Am Acad Dermatol. 2020;82(6):1530–1532.
- De Bruin Weller M, Thaçi D, Smith CH, et al. Dupilumab with concomitant topical corticosteroids in adult patients with AD who are not adequately controlled with or are intolerant to ciclosporin a, or when this treatment is medically inadvisable: a placebo-controlled, randomized phase 3 clinical trial (LIBERTY AD CAFE). Br J Dermatol. 2018;178(5):1083–1101.
- Thaçi D, Simpson L, Deleuran M, et al. Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2). J Dermatol Sci. 2019;94(2):266–275.
- Napolitano M, Di Guida A, Fabbrocini G, et al. Ocular adverse events in patients with atopic dermatitis undergoing treatment with dupilumab: an Italian single-center experience. Dermatol Ther. 2021;34(5):e15059.
- Schmitt J, Schmitt N, Meurer M. Cyclosporin in the treatment of patients with atopic eczema – a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2007;21:606–619.
- Damiani G, Calzavara-Pinton P, Stingeni L, et al. Italian guidelines for therapy of atopic dermatitis-adapted from consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) [published correction appears in Dermatol Ther. 2021 sep;34(5):e15091]. Dermatol Ther. 2019;32(6):e13121.